Cargando…

Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?

Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Słomka, Artur, Wang, Bingduo, Mocan, Tudor, Horhat, Adelina, Willms, Arnulf G., Schmidt-Wolf, Ingo G.H., Strassburg, Christian P., Gonzalez-Carmona, Maria A., Lukacs-Kornek, Veronika, Kornek, Miroslaw T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373826/
https://www.ncbi.nlm.nih.gov/pubmed/35966579
http://dx.doi.org/10.7150/thno.73400
_version_ 1784767670005006336
author Słomka, Artur
Wang, Bingduo
Mocan, Tudor
Horhat, Adelina
Willms, Arnulf G.
Schmidt-Wolf, Ingo G.H.
Strassburg, Christian P.
Gonzalez-Carmona, Maria A.
Lukacs-Kornek, Veronika
Kornek, Miroslaw T.
author_facet Słomka, Artur
Wang, Bingduo
Mocan, Tudor
Horhat, Adelina
Willms, Arnulf G.
Schmidt-Wolf, Ingo G.H.
Strassburg, Christian P.
Gonzalez-Carmona, Maria A.
Lukacs-Kornek, Veronika
Kornek, Miroslaw T.
author_sort Słomka, Artur
collection PubMed
description Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be a game changer in cancer diagnosis or cancer screening. But, during their clinical use limitations were observed from statistical significance and questions raised regarding their robustness, that eventually led to be dropped from associated clinical guidelines for certain applications including cancer diagnosis. The purpose of this review isn't to give a broad overview of all current liquid biopsy as biomarkers, weight them and promise a brighter future in cancer prevention, but rather to take a deeper look on two of those who do qualify to be called liquid biopsies now or then. These two are probably of greatest interest conceptually and methodically, and likely have the highest chances to be in clinical use soon, with a portfolio extension over their original conceptual usage. We aim to dig deeper beyond cancer diagnosis or cancer screening. Actually, we aim to review in depth extracellular vesicles (EVs) and compare with circulating tumour cells (CTCs). The latter methodology is partially FDA approved and in clinical use. We will lay out similarities as taking advantage of surface antigens on EVs and CTCs in case of characterization and quantification. But drawing readers' attention to downstream application based on capture/isolation methodology and simply on their overall nature, here apparently being living material eventually recoverable as CTCs are vs. dead material with transient effects on recipient cell as in case of EVs. All this we try to bring in perspective, compare and conclude towards which future direction we are aiming for, or should aim for. Do we announce a winner between CTCs vs EVs? No, but we provide good reasons to intensify research on them.
format Online
Article
Text
id pubmed-9373826
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-93738262022-08-12 Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? Słomka, Artur Wang, Bingduo Mocan, Tudor Horhat, Adelina Willms, Arnulf G. Schmidt-Wolf, Ingo G.H. Strassburg, Christian P. Gonzalez-Carmona, Maria A. Lukacs-Kornek, Veronika Kornek, Miroslaw T. Theranostics Review Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be a game changer in cancer diagnosis or cancer screening. But, during their clinical use limitations were observed from statistical significance and questions raised regarding their robustness, that eventually led to be dropped from associated clinical guidelines for certain applications including cancer diagnosis. The purpose of this review isn't to give a broad overview of all current liquid biopsy as biomarkers, weight them and promise a brighter future in cancer prevention, but rather to take a deeper look on two of those who do qualify to be called liquid biopsies now or then. These two are probably of greatest interest conceptually and methodically, and likely have the highest chances to be in clinical use soon, with a portfolio extension over their original conceptual usage. We aim to dig deeper beyond cancer diagnosis or cancer screening. Actually, we aim to review in depth extracellular vesicles (EVs) and compare with circulating tumour cells (CTCs). The latter methodology is partially FDA approved and in clinical use. We will lay out similarities as taking advantage of surface antigens on EVs and CTCs in case of characterization and quantification. But drawing readers' attention to downstream application based on capture/isolation methodology and simply on their overall nature, here apparently being living material eventually recoverable as CTCs are vs. dead material with transient effects on recipient cell as in case of EVs. All this we try to bring in perspective, compare and conclude towards which future direction we are aiming for, or should aim for. Do we announce a winner between CTCs vs EVs? No, but we provide good reasons to intensify research on them. Ivyspring International Publisher 2022-08-01 /pmc/articles/PMC9373826/ /pubmed/35966579 http://dx.doi.org/10.7150/thno.73400 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Słomka, Artur
Wang, Bingduo
Mocan, Tudor
Horhat, Adelina
Willms, Arnulf G.
Schmidt-Wolf, Ingo G.H.
Strassburg, Christian P.
Gonzalez-Carmona, Maria A.
Lukacs-Kornek, Veronika
Kornek, Miroslaw T.
Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
title Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
title_full Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
title_fullStr Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
title_full_unstemmed Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
title_short Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
title_sort extracellular vesicles and circulating tumour cells - complementary liquid biopsies or standalone concepts?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373826/
https://www.ncbi.nlm.nih.gov/pubmed/35966579
http://dx.doi.org/10.7150/thno.73400
work_keys_str_mv AT słomkaartur extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT wangbingduo extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT mocantudor extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT horhatadelina extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT willmsarnulfg extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT schmidtwolfingogh extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT strassburgchristianp extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT gonzalezcarmonamariaa extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT lukacskornekveronika extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts
AT kornekmiroslawt extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts